

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

21-246 / S-006

CHEMISTRY REVIEW(S)

SUPPLEMENTAL NDA CHEMIST'S REVIEW		1. ORGANIZATION HFD-530	2. NDA NUMBER 21-246
3. NAME AND ADDRESS OF APPLICANT <i>(City and State)</i> Hoffman-La Roche 340 Kingsland St. Nutley, NJ 08902		4. AF NUMBER	
		5. DOCUMENT(S) NUMBER(S) SCS-006	DATE(S) 09/04/01
6. NAME OF DRUG Tamiflu suspension	7. NONPROPRIETARY NAME Oseltamivir phosphate for oral suspension		
8. SUPPLEMENT(S) PROVIDES FOR: Addition of 25-ml bottle size for more efficient medication use.		9. AMENDMENTS AND DATES SCS-006/BC 10/18/01	
10. PHARMACOLOGICAL CATEGORY Treatment of influenza A and B	11. HOW DISPENSED <input checked="" type="checkbox"/> Rx <input type="checkbox"/> OTC		12. RELATED IND/NDA/DMF(S) IND 53,093, NDA 21,087
13. DOSAGE FORM(S) oral suspension	14. POTENCY(IES)		12 mg/ mL
15. CHEMICAL NAME AND STRUCTURE See current package insert		16. MEMORANDA	
17. COMMENTS <p>Tamiflu suspension is indicated for the treatment of influenza in pediatric and adult patients with dosing based on the weight of the patient. Roche had marketed a single bottle size (75-ml of suspension in a 100-ml bottle) for product launch with enough medication to cover an adult treatment regimen. However, the primary population for this product is children, therefore DAVDP had recommended that a more efficient package size be developed so that less medication would be discarded during pediatric use.</p>			
18. CONCLUSIONS AND RECOMMENDATIONS <p>The proposed 60-ml bottle containing 25-ml of suspension appears comparable in every way to the existing 100-ml bottle containing 75-ml of suspension. It is recommended that the 60-ml bottle presentation be approved in addition to the existing 100-ml bottle.</p>			
19. REVIEWER			
NAME Dan Boring	SIGNATURE <i>/see electronic signature/</i>		DATE COMPLETED 02/25/02
20. CONCURRENCE: HFD-830/SMiller <i>/see electronic signature/</i>			

WITHHOLD 3 **PAGE(S)**

B4

Chemistry Review 1a

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Dan Boring
2/26/02 11:22:07 AM
CHEMIST

Stephen Paul Miller
2/28/02 03:50:36 PM
CHEMIST